Molecular Partners will present three posters at the AACR 2026 Annual Meeting April 17-22 in San Diego. Poster 1624 covers a logic-gated Switch-DARPin T cell engager with CD2 co-stimulation targeting MSLN/EpCAM in ovarian cancer (Session: T Cell Engagers 1, April 20, 9:00 AM–12:00 PM PT). Poster 2691 details a computational workflow for data-driven tumor-antigen profiling in cancer immunotherapies (Session: Bioinformatics to Cancer Biology 3, April 20, 2:00–5:00 PM PT). Poster 7197 describes MP0712, a ²¹²Pb-based Radio-DARPin candidate targeting DLL3 for small cell lung cancer radiotherapy (Session: Targeted Radiopharmaceuticals, April 22, 9:00 AM–12:00 PM PT).

Molecular Partners’ Radio-DARPins use half-life extension and surface engineering to deliver alpha-emitting isotopes precisely to tumor lesions while minimizing kidney accumulation and toxicity. Switch-DARPins provide conditional, tumor-localized immune activation for enhanced safety and potency in next-generation T cell engagers. These platforms leverage intrinsic DARPin properties—small size, high specificity and stability—to address limitations of traditional radioligand and cell-engager therapies.

As a clinical-stage biotech, Molecular Partners advances multiple DARPin programs across preclinical and clinical development, targeting cancer and other diseases. Proprietary libraries and rapid design platforms support both in-house and partnered programs, with a strategic focus on radiopharmaceuticals and immune cell engagers to meet unmet medical needs.